{
  "timestamp": "20250103_151038",
  "model": "gpt-4-turbo",
  "interaction_type": "direct_answer",
  "question_id": "40003db8",
  "question_text": "Anticoagulant of choice for prophylaxis of venous thromboembolism in patient with cancer surgery is:-",
  "messages": [
    {
      "role": "system",
      "content": "You are a medical expert making decisions based on medical knowledge."
    },
    {
      "role": "user",
      "content": "You are a medical expert specializing in the field of Pharmacology.Please help answer this multiple choice question:\n\nQuestion: Anticoagulant of choice for prophylaxis of venous thromboembolism in patient with cancer surgery is:-\n\nOptions:\nopa. Heparin sulfate\nopb. Protamine sulfate\nopc. Low molecular weight heparin\nopd. Warfarin\n\n        ### Output Format\n        Provide your response in valid JSON format:\n        {   \n            \"final_analysis\": \"Your concise analysis following the above structure\",\n            \"answer\": \"Option key from the available options (only key,like opa)\",\n            \"confidence\": Score between 0-100 based on alignment with established medical facts\n        }\n        "
    }
  ],
  "response": "{\n    \"final_analysis\": \"Low molecular weight heparin (LMWH) is generally preferred over unfractionated heparin and other anticoagulants for the prophylaxis of venous thromboembolism (VTE) in patients undergoing cancer surgery. LMWH has been shown to be effective in reducing the risk of VTE in these patients, with a better safety profile, particularly in terms of lower risk of bleeding and better ease of use compared to alternatives like warfarin and unfractionated heparin.\",\n    \"answer\": \"opc\",\n    \"confidence\": 95\n}",
  "metadata": {
    "topic": "Pharmacology",
    "is_multi_choice": true,
    "has_reasoning_chain": false,
    "has_enhanced_info": false,
    "model_config": "gpt-4-turbo",
    "temperature": 0.0
  }
}